Response of Human Pancreatic Cancer Cell Xenografts to Tetraiodothyroacetic Acid Nanoparticles

Murat Yalcin, Hung Yun Lin, Thangirala Sudha, Dhruba J. Bharali, Ran Meng, Heng Yuan Tang, Faith B. Davis, Steven C. Stain, Paul J. Davis, Shaker A. Mousa

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Tetraiodothyroacetic acid (tetrac) and its nanoparticle formulation (Tetrac NP) act at an integrin cell surface receptor to inhibit tumor cell proliferation and tumor-related angiogenesis. Human pancreatic cancer cell (PANC-1 and MPanc96) xenografts were established in nude mice, and the effects of tetrac versus Tetrac NP on tumor growth and tumor angiogenesis were determined. The in vitro effects of tetrac and Tetrac NP were also determined by reverse transcription polymerase chain reaction or immunoblot on gene expression or gene products relevant to cell cycle arrest, apoptosis, or angiogenesis. Tetrac and Tetrac NP reduced both PANC-1 tumor mass by 45-55 % and PANC-1 tumor hemoglobin content, a marker of angiogenesis, by 50-60 % (*P <0.05) in treated groups vs. controls by treatment day 15. Comparable results were obtained with tetrac and Tetrac NP in suppressing tumor growth and tumor angiogenesis in MPanc96 xenografts. In vitro studies showed that tetrac and Tetrac NP caused accumulation of pro-apoptotic protein BcLx-s. Tetrac NP was more effective than tetrac in increasing cellular abundance of mRNAs of pro-apoptotic p53 and p21 and anti-angiogenesis thrombospondin 1 protein in PANC-1 and MPanc96 cancer cell lines. Tetrac NP noticeably decreased expression of EGFR and of anti-apoptosis gene XIAP; tetrac did not affect EGFR and increased XIAP mRNA in both MPanc96 and PANC-1. In conclusion, tetrac or Tetrac NP effectively inhibited human pancreatic xenograft growth and tumor angiogenesis via a plasma membrane receptor that downstream modulated cellular abundance of proteins or mRNAs relevant to apoptosis and angiogenesis.

Original languageEnglish
Pages (from-to)176-185
Number of pages10
JournalHormones and Cancer
Volume4
Issue number3
DOIs
Publication statusPublished - 2013

Fingerprint

Pancreatic Neoplasms
Heterografts
Nanoparticles
Neoplasms
tetraiodothyroacetic acid
Apoptosis
Messenger RNA
Growth
Thrombospondin 1
Apoptosis Regulatory Proteins
Cell Surface Receptors
Cell Cycle Checkpoints
Nude Mice
Integrins
Genes
Reverse Transcription

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Endocrine and Autonomic Systems

Cite this

Response of Human Pancreatic Cancer Cell Xenografts to Tetraiodothyroacetic Acid Nanoparticles. / Yalcin, Murat; Lin, Hung Yun; Sudha, Thangirala; Bharali, Dhruba J.; Meng, Ran; Tang, Heng Yuan; Davis, Faith B.; Stain, Steven C.; Davis, Paul J.; Mousa, Shaker A.

In: Hormones and Cancer, Vol. 4, No. 3, 2013, p. 176-185.

Research output: Contribution to journalArticle

Yalcin, M, Lin, HY, Sudha, T, Bharali, DJ, Meng, R, Tang, HY, Davis, FB, Stain, SC, Davis, PJ & Mousa, SA 2013, 'Response of Human Pancreatic Cancer Cell Xenografts to Tetraiodothyroacetic Acid Nanoparticles', Hormones and Cancer, vol. 4, no. 3, pp. 176-185. https://doi.org/10.1007/s12672-013-0137-y
Yalcin, Murat ; Lin, Hung Yun ; Sudha, Thangirala ; Bharali, Dhruba J. ; Meng, Ran ; Tang, Heng Yuan ; Davis, Faith B. ; Stain, Steven C. ; Davis, Paul J. ; Mousa, Shaker A. / Response of Human Pancreatic Cancer Cell Xenografts to Tetraiodothyroacetic Acid Nanoparticles. In: Hormones and Cancer. 2013 ; Vol. 4, No. 3. pp. 176-185.
@article{907a375bf4ea4b93909f30a12f1753a1,
title = "Response of Human Pancreatic Cancer Cell Xenografts to Tetraiodothyroacetic Acid Nanoparticles",
abstract = "Tetraiodothyroacetic acid (tetrac) and its nanoparticle formulation (Tetrac NP) act at an integrin cell surface receptor to inhibit tumor cell proliferation and tumor-related angiogenesis. Human pancreatic cancer cell (PANC-1 and MPanc96) xenografts were established in nude mice, and the effects of tetrac versus Tetrac NP on tumor growth and tumor angiogenesis were determined. The in vitro effects of tetrac and Tetrac NP were also determined by reverse transcription polymerase chain reaction or immunoblot on gene expression or gene products relevant to cell cycle arrest, apoptosis, or angiogenesis. Tetrac and Tetrac NP reduced both PANC-1 tumor mass by 45-55 {\%} and PANC-1 tumor hemoglobin content, a marker of angiogenesis, by 50-60 {\%} (*P <0.05) in treated groups vs. controls by treatment day 15. Comparable results were obtained with tetrac and Tetrac NP in suppressing tumor growth and tumor angiogenesis in MPanc96 xenografts. In vitro studies showed that tetrac and Tetrac NP caused accumulation of pro-apoptotic protein BcLx-s. Tetrac NP was more effective than tetrac in increasing cellular abundance of mRNAs of pro-apoptotic p53 and p21 and anti-angiogenesis thrombospondin 1 protein in PANC-1 and MPanc96 cancer cell lines. Tetrac NP noticeably decreased expression of EGFR and of anti-apoptosis gene XIAP; tetrac did not affect EGFR and increased XIAP mRNA in both MPanc96 and PANC-1. In conclusion, tetrac or Tetrac NP effectively inhibited human pancreatic xenograft growth and tumor angiogenesis via a plasma membrane receptor that downstream modulated cellular abundance of proteins or mRNAs relevant to apoptosis and angiogenesis.",
author = "Murat Yalcin and Lin, {Hung Yun} and Thangirala Sudha and Bharali, {Dhruba J.} and Ran Meng and Tang, {Heng Yuan} and Davis, {Faith B.} and Stain, {Steven C.} and Davis, {Paul J.} and Mousa, {Shaker A.}",
year = "2013",
doi = "10.1007/s12672-013-0137-y",
language = "English",
volume = "4",
pages = "176--185",
journal = "Hormones and Cancer",
issn = "1868-8497",
publisher = "Springer US",
number = "3",

}

TY - JOUR

T1 - Response of Human Pancreatic Cancer Cell Xenografts to Tetraiodothyroacetic Acid Nanoparticles

AU - Yalcin, Murat

AU - Lin, Hung Yun

AU - Sudha, Thangirala

AU - Bharali, Dhruba J.

AU - Meng, Ran

AU - Tang, Heng Yuan

AU - Davis, Faith B.

AU - Stain, Steven C.

AU - Davis, Paul J.

AU - Mousa, Shaker A.

PY - 2013

Y1 - 2013

N2 - Tetraiodothyroacetic acid (tetrac) and its nanoparticle formulation (Tetrac NP) act at an integrin cell surface receptor to inhibit tumor cell proliferation and tumor-related angiogenesis. Human pancreatic cancer cell (PANC-1 and MPanc96) xenografts were established in nude mice, and the effects of tetrac versus Tetrac NP on tumor growth and tumor angiogenesis were determined. The in vitro effects of tetrac and Tetrac NP were also determined by reverse transcription polymerase chain reaction or immunoblot on gene expression or gene products relevant to cell cycle arrest, apoptosis, or angiogenesis. Tetrac and Tetrac NP reduced both PANC-1 tumor mass by 45-55 % and PANC-1 tumor hemoglobin content, a marker of angiogenesis, by 50-60 % (*P <0.05) in treated groups vs. controls by treatment day 15. Comparable results were obtained with tetrac and Tetrac NP in suppressing tumor growth and tumor angiogenesis in MPanc96 xenografts. In vitro studies showed that tetrac and Tetrac NP caused accumulation of pro-apoptotic protein BcLx-s. Tetrac NP was more effective than tetrac in increasing cellular abundance of mRNAs of pro-apoptotic p53 and p21 and anti-angiogenesis thrombospondin 1 protein in PANC-1 and MPanc96 cancer cell lines. Tetrac NP noticeably decreased expression of EGFR and of anti-apoptosis gene XIAP; tetrac did not affect EGFR and increased XIAP mRNA in both MPanc96 and PANC-1. In conclusion, tetrac or Tetrac NP effectively inhibited human pancreatic xenograft growth and tumor angiogenesis via a plasma membrane receptor that downstream modulated cellular abundance of proteins or mRNAs relevant to apoptosis and angiogenesis.

AB - Tetraiodothyroacetic acid (tetrac) and its nanoparticle formulation (Tetrac NP) act at an integrin cell surface receptor to inhibit tumor cell proliferation and tumor-related angiogenesis. Human pancreatic cancer cell (PANC-1 and MPanc96) xenografts were established in nude mice, and the effects of tetrac versus Tetrac NP on tumor growth and tumor angiogenesis were determined. The in vitro effects of tetrac and Tetrac NP were also determined by reverse transcription polymerase chain reaction or immunoblot on gene expression or gene products relevant to cell cycle arrest, apoptosis, or angiogenesis. Tetrac and Tetrac NP reduced both PANC-1 tumor mass by 45-55 % and PANC-1 tumor hemoglobin content, a marker of angiogenesis, by 50-60 % (*P <0.05) in treated groups vs. controls by treatment day 15. Comparable results were obtained with tetrac and Tetrac NP in suppressing tumor growth and tumor angiogenesis in MPanc96 xenografts. In vitro studies showed that tetrac and Tetrac NP caused accumulation of pro-apoptotic protein BcLx-s. Tetrac NP was more effective than tetrac in increasing cellular abundance of mRNAs of pro-apoptotic p53 and p21 and anti-angiogenesis thrombospondin 1 protein in PANC-1 and MPanc96 cancer cell lines. Tetrac NP noticeably decreased expression of EGFR and of anti-apoptosis gene XIAP; tetrac did not affect EGFR and increased XIAP mRNA in both MPanc96 and PANC-1. In conclusion, tetrac or Tetrac NP effectively inhibited human pancreatic xenograft growth and tumor angiogenesis via a plasma membrane receptor that downstream modulated cellular abundance of proteins or mRNAs relevant to apoptosis and angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84877029051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877029051&partnerID=8YFLogxK

U2 - 10.1007/s12672-013-0137-y

DO - 10.1007/s12672-013-0137-y

M3 - Article

C2 - 23456390

AN - SCOPUS:84877029051

VL - 4

SP - 176

EP - 185

JO - Hormones and Cancer

JF - Hormones and Cancer

SN - 1868-8497

IS - 3

ER -